Standing disclosure
What this is
A numbered archive of securities research assembled from primary sources — SEC filings, FINRA data, corporate records demands, and correspondence. Every figure here carries instructions for reproducing it. Nothing on this site asks the reader to take the author's word for anything.
Position. The author holds shares of Theriva Biologics, Inc. (NYSE American: TOVX) and has held them for more than four years. The author formerly held shares of iBio, Inc. (IBIO) and sold that position at a profit.
No allegation of wrongdoing. These reports describe transactions that were disclosed in filings made with the Securities and Exchange Commission. Representing issuers in registered offerings, acting as placement agent, and serving on a board of directors are lawful activities. No report on this site alleges that any person or firm has broken any law.
Triggered Short™ is the author's own descriptive term for a financing pattern. It is not an established legal, regulatory, or accounting concept.
Series index
Reports
Subject: Theriva Biologics, Inc. (NYSE American: TOVX), formerly Synthetic Biologics, Inc. SEC CIK 0000894158.
Executive Summary — the Triggered Short™ model
Capital structure since 2025, the May 2025 financing, the October 2025 warrant inducement, and the hypothetical model, with all calculations marked illustrative. Published July 20, 2026.
Summary
Findings only, numbered, each pointing to the report that carries the support.
The record requests
The stockholder meeting of December 15, 2025; three consecutive meetings called without a quorum; sworn demands for inspection of corporate records; the company's rejection through outside counsel; certified mail documentation and return receipts.
The warrant cycle
Issue, decline, repricing, replacement warrants at 200 percent, exercise. Documented from company filings only. Includes a dated forward prediction.
The market record
FINRA reported short interest, FINRA average daily volume, price and volume history, and turnover against shares outstanding, set against the filing dates in 2B. Third-party data only.
Professional recurrence — Exhibit J
Counsel, placement agent, and directors appearing across multiple issuers in the same financing structure. Counts drawn from EDGAR full-text search.
Correspondence
Requests for comment
Four letters were sent before publication, each setting out the specific statements of fact intended for print and inviting correction. Each letter states that any response will be published in full and unedited.
| Recipient | Attention | Delivered | Response due |
|---|---|---|---|
| Theriva Biologics, Inc. | Chief Executive Officer; Corporate Secretary | Aug 12, 2026 | Aug 19, 2026 |
| A.G.P. / Alliance Global Partners | Chief Compliance Officer | Aug 12, 2026 | Aug 19, 2026 |
| Blank Rome LLP | Leslie Marlow | Aug 12, 2026 | Aug 19, 2026 |
| Empery Asset Management, LP | Managing Members | Aug 12, 2026 | Aug 19, 2026 |
Responses received will be posted here in full. Where no response is received, that will be stated.
Reproduce it yourself
Every ownership figure in this docket came from the same free tool. It takes about ten minutes.
- Open sec.gov/edgar/search — the SEC's full-text search, covering electronic filings since 2001.
- Type a name in quotation marks and press Search. For example:
"Empery Asset Management" - On the results page, open the Entity panel on the left. It lists every filer whose documents contain that phrase, with a count for each.
- Use Show Columns → Incorporated to add each issuer's state or country of incorporation to the results table.